At this year's ASH congress, the results of the phase 1b/2 DURGA-1 of AZD0120 – a dual BCMA and CD19-directed CAR-T therapy – ...

The verdict is the latest twist in patent litigation between MSD and Halozyme, in which the latter is claiming that Keytruda ...

CD19-targeted therapy Breyanzi (lisocabtagene maraleucel) can now be used to treat adults with MZL – a rare and form of ...

Protego Biopharma is poised to start pivotal trials of its amyloid light-chain (AL) amyloidosis drug candidate, thanks to a ...

Bayer has started a phase 3 trial of its intrauterine contraceptive Mirena in an endometrial condition that can lead to ...

Eli Lilly's fast-growing blood cancer drug Jaypirca has bagged a new FDA approval as an earlier treatment for relapsed or ...

The EMBOLD study of relutrigine (also known as PRAX-562) was testing the oral drug in patients with SCN2A and SCN8A ...

The FDA has now started a review of the highly anticipated drug, and AZ is using a priority review voucher to shorten the ...

For decades, contract development and manufacturing organisations (CDMOs) have operated through fragmented models, with drug ...

From antibody–drug conjugates (ADCs) moving into early-stage disease to arenavirus-based immunotherapies and ctDNA-guided ...

Despite their readiness, blood centres remain an underutilised lever in pharma’s innovation model. As industry players seek ...

At Frontiers Health 2025, Drew McCormick, Head of Data and Analytics at EVERSANA, emphasised a critical truth: data strategy ...